Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Down 13.4% in October

Check-Cap Ltd. (NASDAQ:CHEK) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 14,200 shares, a decrease of 13.4% from the October 15th total of 16,400 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily volume of 14,900 shares, the short-interest ratio is currently 1.0 days.

Check-Cap Stock Performance

NASDAQ CHEK traded down $0.03 on Friday, reaching $0.77. The company’s stock had a trading volume of 25,887 shares, compared to its average volume of 28,581. Check-Cap has a twelve month low of $0.76 and a twelve month high of $3.85. The stock has a market cap of $4.53 million, a PE ratio of -0.26 and a beta of 0.39. The firm’s 50 day moving average is $1.37 and its two-hundred day moving average is $1.82.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on Check-Cap in a research note on Sunday. They set a “sell” rating on the stock.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.